

Information and consent for the patient support program for specialty drugs

Please fill out this page only if you live outside Quebec.

INFORMATION

The prescription drug that is the object of your request is part of our patient support program. Designed to help you better manage your medical condition, this program provides you with many benefits such as access to professional support from a team of pharmacists. For more information, see the *Prior Authorization Drugs and the Patient Support Program* brochure, available at www.desjardinslifeinsurance.com/PAD.

If your contract includes the program, you may be required to participate.

A healthcare professional from the provider selected by Desjardins Insurance will contact you to let you know the status of your request, to explain how the program works and to direct you to a preferred pharmacy. That professional may also contact your attending physician to get any missing information. The information obtained as a result of this prior authorization request will be sent to the third party and used to process your request. This is why your signature is required.

IMPORTANT

As part of the patient support program, you will be reimbursed for your specialty drug only if you purchase it through the preferred pharmacy network.

CONSENT TO DISCLOSE TO A THIRD PARTY

For the sole purpose of the patient support program, I authorize Desjardins Insurance to disclose to the third party personal information about me, especially my medical information, that is needed for the program. I understand that the third party may share this information with my doctors, pharmacists and other healthcare professionals as part of this program.

This consent also applies to the disclosure of personal information concerning my dependents, insofar as this request involves them.

Last name and first name of the member (PLEASE PRINT)	Contract No.	Certificate No.	
Email address of the member			
Signature of the member		Date	
Last name and first name of the parent or legal guardian (if ne	cessary)		
Signature of the parent or legal guardian (if necessary)		Date	

This consent is an integral part of the attached Prior Authorization Request form.



C. P. 3950 Lévis (Québec) G6V 8C6 desjardinslifeinsurance.com/planmember

Tel.: 1-844-410-6485 Fax: 1-877-838-2134 418-838-2134

PRIOR AUTHORIZATION REQUEST

CINQAIR (RESLIZUMAB)
FASENRA (BENRALIZUMAB)
TEZSPIRE (TEZEPELUMAB)

PLEASE READ THE INSTRUCTIONS ON THE LAST PAGE OF THIS FORM.

Α	PATIENT IDENTIFICATI	ION – To be completed by the member.						
	Patient's last and first nam	e	Relationship w	ith member		Patient's da		
			Member	Spouse	Dependent child	d YYYY	MM DD	
	Member's last and first na	ember's last and first name Contract No.				Certificate No.		
	No., street, apt.					Province	Postal code	
	Telephone Nos – Home:	Office:	Extensio	n:	Email:			
	Since the response to this request includes confidential information, please indicate how you would like to be in				ned of the decision:			
	☐ By mail (The response t	to your request will be sent to the address indicated in thi	s section.)	☐ By fax:				
	Coordination of benefits: If the patient has coverage under a private insurance plan or is enrolled in a provincial drug insurance plan, please submit the request to this plan first. Then send us a copy of the decision notice and this form filled out by the physician, so we can analyze the request.							
		Does the patient have drug coverage under a private i	insurance plan?					
		☐ Yes – Please provide a copy of the notice of approv	•	→ □Сору	attached to this forn	n.		
	PRIVATE PLAN	Specify: Name of the insurer:		Contract No :	i	Certificate No.		
		□ No				_ 00110010 110		
		Has a request for reimbursement been submitted und	der your provinci	ial plan?				
	PROVINCIAL PLAN	Yes – Please provide a copy of the notice of approv	val or refusal	→ □ Copy	attached to this forr	n.		
□ No – Please explain:								
		Is the patient enrolled in a patient support program?	Yes No)				
	PATIENT SUPPORT PROGRAM	If so – Program name:						
	PROGRAM	Contact person:		Telephone	e No.:	E	Extension:	
В1	DECLARATION AND AU	UTHORIZATION FOR THE COLLECTION AND COM	MUNICATION	N OF PERSON	IAL INFORMATIO	N		
	All the information I have provided on the claim form is accurate and complete. I authorize Desjardins Financial Security Life Assurance Company, hereinafter Desjardins Insurance, strictly for the purposes of managing my file and settling this claim to: (a) collect from any person or legal entity, or from any public or parapublic organization, only the information deemed necessary to manage my file. The non-exhaustive list of sources from which information may be collected includes healthcare professionals or facilities, and insurance companies; (b) communicate to the said persons or organizations only the personal information about me that is deemed necessary for the purposes of my file; (c) when necessary use the personal information it may have about me in existing files that are now closed. This authorization is also valid for the collection, use and communication of personal information concerning my dependents, insofar as applicable to the claim. A photocopy of this authorization is as valid as the original.							
>	Signature of member: Date:							
	Last name and first name of parent/legal guardian (if applicable):							
	Signature of patient or par	rent/legal guardian (if applicable):			Date:			
B2	CONSENT TO THE CON	MMUNICATION OF PERSONAL INFORMATION TO	A THIRD PAR	RTY				
	To help us process your claim more efficiently, do you authorize Desjardins Insurance to inform the patient support program and the attending physician or the attending physician or the decision on your prior authorization request?						rsician or the attending	
Yes No								
>	Signature of member:				_ Date:			
Last name and first name of parent/legal guardian (if applicable):								
	Signature of patient or par	rent/legal guardian (if applicable):			Date:			

CONTINUED ON THE BACK

ATTENDING PHYSICIAN SECTION – To be completed by the attending physician.								
Physician's last and first name (PLEASE PRINT)		Licer	nse No.	Specialty				
No., street, suite	street, suite City I					Postal code		
Telephone No.:	Telephone No.: Fax No.:							
Signature of physician:				Date:				
Drug name	Formulation	Strength	Dosage	Patient's weight	Scheduled dur	ration of treatment		
_	Where is the drug administered?							
IMPORTANT – The physician must have previously verified the inhalation technique, adherence to pharmacological treatment and the implementation of strategies to reduce exposure to pneumallergens to which the person obtained a positive result during skin test or in vitro reactivity test.								
 Make sure to fill out all sections so we can process the request faster. If any information is missing, we will send the form back to the member. In order to consider any diagnosis not mentioned on this form, we need supporting documents (clinical practice guidelines, clinical studies, etc.) that justify the drug's use in the given context. 								
DIAGNOSIS								
Severe asthma	Severe asthma in	n patients receivir	ng oral corticostero	oids for more than 3	3 months			
Other therapeutic indication(s) – Please specify:								
INFORMATION RELATING TO DIAGNOSTIC								
Has the patient experienced asthma exacerbations requiring	ng the use of systemic o	corticosteroid in th	ne past 12 months	? □Yes □No	How many	/:		
If the patient is already under continuous systemic corticos	steroid therapy, please	provide:						
Date of initiation of oral corticosteroid therapy:								
The number of exacerbations requiring a dose increase in	n the last 12 months: $_$							
Corticosteroid used ans dosage:		_						
Blood eosinophil at initiation of treatment:		cells/μL						
Blood eosinophil in past twelve months:		cells/μL						
Please provide results for at least one of the following que	stionnaires:							
Asthma Control Questionnaire (ACQ):	_ St	George's Respirat	ory Questionnaire	(SGRQ):		-		
Asthma Control Test (ACT): Asthma Quality of Life Questionnaire (AQLQ):								
PRIOR MEDICATION OR TREATMENT Has the patient ever used medication or received treatment for this medical condition? Yes No If not, please explain:								
If so, please list any medication already used or any treatm	ent already received fo	or this medical cor	ndition:					
MEDICATION OR TREATMENT NAME	MEDICATION OR TREATMENT NAME OUTCOME TREATMENT PERIOD							
Name:	Inefficien	cy Intolera	nce Contra	indication	From:	YYYY MM DD		
Dose:	Specify:				То:	YYYY MM DD		
Name:	Inefficien	cy Intolera	nce Contra	indication	From:	YYYY MM DD		
Dose:	Specify: To:					YYYY MM DD		
Name: Inefficiency Intolerance Contraindication From:								
Dose: Specify: To:								
Name: Inefficiency Intolerance Contraindication From:								
Dose:	Specify:				To:	YYYY MM DD		

С

Severe asthma - Please provide results for at least one of the following questionnaires: Asthma Control Questionnaire (ACQ): ______ St George's Respiratory Questionnaire (SGRQ): ______ Asthma Control Test (ACT): ______ Asthma Quality of Life Questionnaire (AQLQ): ______ Number of exacerbations annually under treatment: ______ Severe asthma in patients receiving oral corticosteroids for more than 3 months

D INSTRUCTIONS – HOW TO COMPLETE AND RETURN THIS FORM

1. Complete sections A and B.

Corticosteroid used: _

PRESCRIPTION RENEWAL

2. Ask your physician to complete section C. The member is responsible for assuming any costs incurred to complete this form or to obtain additional information.

Dosage: _

3. To obtain a reimbursement once the drug has been approved, please use your payment card at the pharmacy or submit your original receipts by mail. Eligible drugs must be dispensed by a pharmacist or a physician, if there is no pharmacist.

4. Send form: • by fax: Designatins Insurance

ATTENDING PHYSICIAN SECTION – Continued

Group Insurance, Health Claims,

418-838-2134 or 1-877-838-2134 (toll-free)

• by mail: Desjardins Insurance

Group Insurance, Health Claims C. P. 3950, Lévis (Québec) G6V 8C6

Under its prior authorization program, Desjardins Insurance authorizes the reimbursement of certain drugs that meet criteria that are based, in particular, on clinical practice guidelines and recommendations issued by health technology assessment organizations. The drug will be eligible for reimbursement if it meets the insurer's criteria, if it's not administered in a hospital and if it's not eligible under a government program. If the information on your form is complete, your request will normally be processed within 5 business days.

When the request form is received, it will be assessed in the strictest confidence. In some situations, additional diagnostic or clinical information may be required.

If the treatment continues beyond the authorized period, you will be asked to submit a new request form and provide information that justifies the extension of treatment. If you have a payment card, your pharmacist will be advised that the authorization period is coming to an end. The insurance must be in force and the patient still covered on the date expenses are incurred. This prior authorization is subject to change if, at the time expenses are incurred, the contract has been modified.

When Desjardins Insurance declines a prior authorization request, it is because we need to uphold conditions set out in the contract. It does not mean we are questioning the physician's opinion. If you have any questions, please contact our Customer Contact Centre at the number indicated on page 1 of this form.